Register Now
Panelists:
Zhongyao Ma, PhD
Senior Director, Head of Target Discovery and Validation & Peptide Discovery PlatformWuXi Biology, WuXi AppTec
View Bio
Panelist
Zhongyao Ma, PhD
Zhongyao Ma, PhD, holds a bachelor’s degree in biology from Shanghai Jiao Tong University and a PhD in genetics and developmental biology from the University of Georgia, U.S. His research focused on thymic epithelial cell reprogramming and developmental regulation. In early 2021, Ma joined WuXi AppTec and assumed a position at the China Research and Development Center. He is responsible for expanding the application of DNA Encoded Library (DEL) technology across more discovery scenarios, as well as leading the peptide discovery platform and the target science platform.
Close
Wenzhang Chen, PhD
Senior Director, Head of Biomass Spectrometry PlatformWuXi Biology, WuXi AppTec
View Bio
Panelist
Wenzhang Chen, PhD
Wenzhang Chen, PhD, has 25 years of expertise in biomass spectrometry and proteomics analysis. He earned his PhD in bioanalytical chemistry from Zhejiang University and subsequently served as a scientific officer at the College of Life Sciences, University of Dundee. In 2017, he joined Shanghai Tech University, where he led a bioanalytical chemistry facility focusing on the development of mass spectrometry and proteomics methodologies. Currently, Wenzhang Chen heads a biomass spectrometry platform at WuXi AppTec, where his team provides mass spectrometry-based drug screening, proteomics, and bioanalysis services to global clients.
Close
Broadcast Date: Thursday, January 15, 2026Time: 08:00 PST, 11:00 EST, 16:00 GMTTarget deconvolution, particularly when paired with proteomics techniques, plays a crucial role in drug screening, covalent drug discovery, mechanism of action (MOA) discovery, and target identification. By using chemical proteomics, researchers can more precisely identify interactions between small molecules and cellular targets, aiding in the development of new therapeutic candidates.In this GEN webinar, our expert speakers will explore cutting-edge drug discovery techniques for target deconvolution and multiplex target discovery. They will also delve into how multiplex target discovery and target tractability assessment accelerate the drug discovery process. Attendees will learn how to apply target discovery and target deconvolution technologies in the early stages of drug development, enabling faster, more accurate identification of viable drug targets. Additionally, the experts will discuss the use and value of DNA-encoded libraries for target tractability assessment. Attendees will learn about the technical strengths and service opportunities available through WuXi Apptec. Key takeaways from the webinar include:Accelerating drug discovery and MOA studies through proteomics and target deconvolution.Applying multiplex target discovery and deconvolution techniques to identify promising drug targets.Leveraging DNA-encoded libraries for efficient target tractability assessment.A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.Produced with support from:The post Drug Discovery Innovation: Target Deconvolution and Tractability Assessment appeared first on GEN – Genetic Engineering and Biotechnology News.
